Subcutaneous Mastectomy with Lymphadenectomy and Irradiation for Primary Treatment of Breast Cancer

1985 ◽  
pp. 296-309 ◽  
Author(s):  
F. K. Beller ◽  
E. H. Schmidt
Keyword(s):  
Breast Cancer ◽  
Primary Treatment ◽  
Subcutaneous Mastectomy

Primary Treatment of Breast Cancer

1982 ◽  
Vol 25 (2) ◽  
pp. 425-431
Author(s):  
David H. Nichols
Keyword(s):  
Breast Cancer ◽  
Primary Treatment

scholarly journals Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial

2009 ◽  
Vol 100 (3) ◽  
pp. 442-449 ◽  
Author(s):  
A Barnadas ◽  
M Gil ◽  
S González ◽  
I Tusquets ◽  
M Muñoz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Postmenopausal Women ◽  
Phase Ii ◽  
Oestrogen Receptor ◽  
Phase Ii Trial ◽  
Primary Treatment ◽  
Positive Breast Cancer

Evaluation of CD34 antigen expression following tamoxifen as primary treatment for breast cancer

2006 ◽  
Vol 93 (1) ◽  
pp. 70-71 ◽  
Author(s):  
B.B. da Silva ◽  
E.R. de Carvalho Gonçalves Nunes Galvão ◽  
L.G. dos Santos
Keyword(s):  
Breast Cancer ◽  
Antigen Expression ◽  
Primary Treatment ◽  
Cd34 Antigen

Clinical analysis of endoscopic and open subcutaneous mastectomy in the treatment of early breast cancer

2021 ◽  
Author(s):  
Pengfei LYU ◽  
Yu WANG ◽  
Pingming FAN ◽  
Wuping ZHENG ◽  
Xinrui LIANG
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Clinical Analysis ◽  
Subcutaneous Mastectomy

scholarly journals Systemic treatment approaches in her2-negative advanced breast cancer—guidance on the guidelines

2015 ◽  
Vol 22 ◽  
pp. 29 ◽  
Author(s):  
A.A. Joy ◽  
M. Ghosh ◽  
R. Fernandes ◽  
M.J. Clemons
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
De Novo ◽  
Treatment Guidelines ◽  
Early Stage ◽  
Symptom Control ◽  
Growth Factor Receptor ◽  
Disease Recurrence ◽  
Primary Treatment ◽  
Advanced Breast

Despite advancements in the treatment of early-stage breast cancer, many patients still develop disease recurrence; others present with de novo metastatic disease. For most patients with advanced breast cancer, the primary treatment intent is noncurative—that is, palliative—in nature. The goals of treatment should therefore focus on maximizing symptom control and extending survival. Treatments should be evaluated on an individualized basis in terms of evidence, but also with full respect for the wishes of the patient in terms of acceptable toxicity. Given the availability of extensive reviews on the roles of endocrine therapy and her2 (human epidermal growth factor receptor 2)–targeted therapies for advanced disease, we focus here mainly on treatment guidelines for the non-endocrine management of her2-negative advanced breast cancer in a Canadian health care context.

Ca 15.3 as a Tumour Marker in Breast Cancer

1987 ◽  
Vol 2 (3) ◽  
pp. 135-142 ◽  
Author(s):  
Peter Schmidt-Rhode ◽  
Klaus-Dieter Schulz ◽  
Gerhard Sturm ◽  
Anette Raab-Frick ◽  
Helge Prinz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Marker ◽  
Primary Treatment ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Ca 15.3 ◽  
Healthy Females

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between < 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% ofpatients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

Measuring standards of care for early breast cancer in an insured population.

1997 ◽  
Vol 15 (4) ◽  
pp. 1401-1408 ◽  
Author(s):  
B E Hillner ◽  
M K McDonald ◽  
L Penberthy ◽  
C E Desch ◽  
T J Smith ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ct Scan ◽  
Bone Scan ◽  
Best Practice ◽  
Clinical Stage ◽  
Primary Treatment ◽  
Standards Of Care ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
International Consensus

PURPOSE To demonstrate the use of a combined data base to evaluate the care for local/regional invasive breast cancer in a large insured population of women aged less than 64 years. PATIENTS AND METHODS We linked the procedural and hospital claims from Blue Cross Blue Shield (BCBS) of Virginia with clinical stage data from the Virginia Cancer Registry (VCR) from 1989 to 1991. A total of 918 women were assessed with a median age of 50 years; 68% had tumors less than 2 cm, 30% had positive axillary nodes, and 68% were assessed as having local summary stage. A quality-of-care "report card" was used based on standards of care from international Consensus Conferences. RESULTS Eight percent had a mastectomy as the initial biopsy procedure. Sixty-nine percent of women ultimately underwent mastectomy. Of those women who underwent lumpectomy, 86% had subsequent radiation. Within 3 months of diagnosis, 43% had a bone scan and 20% a computed tomography (CT) scan. Of women with positive axillary lymph nodes, 83% aged less than 51 years and 52% aged 51 to 64 years received chemotherapy. Fifty-six percent of all women had claims from a medical oncologist. Of women having a total mastectomy, 27% had claims from a plastic surgeon. Sixty-six percent to 76% of women had a mammogram, 24% a bone scan, and 14% a CT scan in the 0-18 and 18-36 month intervals following primary treatment. CONCLUSION This study confirms the feasibility of linking sources of data that provide complementary information needed to develop measurements regarding standards of quality and efficiency of oncologic care. This report should serve as an initial benchmark while we await reports from other populations to define the best practice.

Sign in / Sign up

Export Citation Format

Share Document